Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7241571 | 1.00 | TBXAS1 (0.47) | TBXAS1CYP19A1 | |
| SCHEMBL7246582 | 0.88 | KDM4E (0.48) | TBXAS1CYP19A1 | |
| SCHEMBL7246585 | 0.88 | KDM4E (0.48) | TBXAS1CYP19A1 | |
| SCHEMBL7241462 | 0.86 | CYP19A1 (0.41) | TBXAS1CYP19A1 | |
| SCHEMBL7241459 | 0.86 | CYP19A1 (0.41) | TBXAS1CYP19A1 | |
| SCHEMBL8206727 | 0.81 | AGTR2 (0.44) | TBXAS1 | |
| SCHEMBL8206718 | 0.81 | AGTR2 (0.44) | TBXAS1 | |
| SCHEMBL8212192 | 0.81 | FNTA (0.44) | — | |
| SCHEMBL8212186 | 0.81 | FNTA (0.44) | — | |
| SCHEMBL7703360 | 0.80 | CYP11B1 (0.40) | TBXAS1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220495-A1 | Inhibitors of farnesyl protein transferase | ZENECA LIMITED AND ZENECA PHARMA S.A. | 2003-11-27 | — | — | US | disclosed |
| US-6414145-B1 | TREATING CANCER AND NEUROFIBROMATOSIS | ZENECA LIMITED (GB) | 2002-07-02 | — | — | US | disclosed |
| EP-0975603-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | ZENECA LIMITED (GB) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998032741-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | ZENECA LIMITED (GB) | 1998-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220495-A1 | Inhibitors of farnesyl protein transferase | KRAS, FNTA, FNTB | TBXAS1 1494/4885CYP19A1 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.